The Genentech Foundation is a U.S.-based, private charitable foundation whose donations are made possible by contributions from Genentech. Genentech is committed to being a strong corporate citizen, and the Genentech Foundation is one of the most important ways in which we give back to our communities.
Carla Boragno, Board Chair and Senior Vice President and Global Head of Engineering and Facilities, Pharma Technical Operations
Susan Begelman, MD, Vice President, US Respiratory Franchise
Mary Cromwell, Vice President, Pharma Technical Quality Drug Substance
Mark Eisner, M.D., M.P.H., Senior Vice President and Global Head of Immunology, Infectious Disease and Ophthalmology Clinical Development
Sarah Hymowitz, Ph.D., Vice President, Protein Sciences
Sean Johnston, Ph.D., J.D., Senior Vice President, General Counsel, and Chief Compliance Officer
Sara Kenkare-Mitra, Ph.D., Senior Vice President, Development Sciences
Allen Napetian, Vice President, Site Services
Eric J. Olson, Vice President, US Product Development Regulatory
Geoff Teeter, Vice President, Corporate Relations
With more than 30 years of experience in engineering, manufacturing, procurement and site management, Carla brings unique insight and expertise to her role as Senior Vice President, Head of Global Engineering and Facilities for Roche. In this role, Carla is responsible for the design, construction, maintenance and life-cycle asset management for Roche’s global manufacturing network.
Throughout her varied and successful career at Genentech and Roche, Carla is known as a transformational business leader across functions and geographies. In her prior role, Carla was the Vice President of Site Services for Genentech, where she was responsible for Genentech’s real-estate portfolio, physical infrastructure, and workplace services for the South San Francisco headquarters, consisting of 200 acres, approximately five million square feet of space supporting more than 11,000 employees. Prior to her role in Site Services, Carla served as the Head of Procurement Services for Roche’s Global Pharma team, she was responsible for strategic and operational procurement services across the Roche organization. While based in Singapore, she led the transition and full integration of a newly acquired manufacturing facility into Roche’s existing Singapore operations. She also owned the successful implementation for $1.5B capital design and construction portfolio during a critical growth time for Genentech 2004-2008.
Carla is a true change agent, with a passion for motivating and inspiring talent and building high-performing teams. She is a respected mentor at Roche, in the industry and the local community. Carla serves on the Board of Directors for Bay Area Council and is a member of the International Women’s Forum. Carla is a thought leader and sought after inspirational speaker.
Susan Begelman is the Vice President of the US Respiratory Franchise at Genentech. In this role, she leads a cross-functional team accountable for the development and implementation of integrated business and medical strategies focused on making medical progress for patients, addressing customer needs, and delivering on business objectives for this therapeutic area.
Susan is widely regarded as a respected leader with an unwavering commitment to patients. She has over fourteen years of experience in biopharmaceutical industry. Since joining Genentech in 2008, Susan has overseen product development activities and provided oversight of medical launch strategies and phase 3b/4 trials in multiple therapeutic areas that include cardiovascular disease, neuroscience, rare disease, and stroke. In her previous position, she was the Vice President of the Neuroscience, Rare Blood Disorders, Influenza, and Established Product Unit in US Medical Affairs. Prior to joining the biopharmaceutical industry, she was an academic vascular medicine physician in the Department of Cardiovascular Medicine and Medical Director of the Noninvasive Vascular Laboratory at the Cleveland Clinic for six years.
Susan received a Bachelor of Arts in Biology from the University of Pennsylvania and her Medical Doctorate from Hahnemann University School of Medicine (now called Drexel University College of Medicine) in Philadelphia. She completed her residency in internal medicine and fellowship in vascular medicine at the Cleveland Clinic. Susan is a fellow of the Society for Vascular Medicine for which she was a Committee Chair and held elected positions as a Board of Trustees Member, Secretary, and Treasurer. Susan is also a fellow of the American College of Cardiology.
"I am proud to be on the Board of the Genentech Foundation, an organization focused on investing in our local communities to remove barriers that will enable all people with a passion for science and medicine to pursue related careers."
Based in South San Francisco, Mary began her career at Genentech in 1989 in the Pharmaceutical Development group where she developed formulations for a number of molecules in various stages of development, including Avastin®. She has held leadership positions in Protein Analytical Chemistry, Pharmaceutical Development, and Global Biologics MSAT & Global Packaging Development and has provided leadership in key initiatives including Quality by Design for Control Strategy and CMContinuum. As of June 2018, Mary became the Head of Global Quality Drug Substance. Mary received a B.S. in Chemistry from West Virginia University, an M.S.in Biophysical Chemistry from the University of California-Berkeley, and a Ph.D. in Pharmaceutical Sciences from the University of Colorado-Denver.
Mark Eisner is Senior Vice-President, Global Head of Product Development I2O (Immunology, Infectious Disease, and Ophthalmology) at Genentech. He joined Genentech in 2010 as an Associate Group Medical Director and has taken on increasing level of responsibility culminating in his current role as SVP. Mark has led the Actemra clinical science group that secured global regulatory approvals for Actemra subcutaneous formulation, polyarticular JIA, Giant Cell Arteritis, cytokine release syndrome and pediatric indications (subcutaneous formulation for sJIA and pJIA.) More recently, Mark has built the late development group that gained FDA approval of Xofluza, which is the first new mechanism of action for influenza in 20 years.
Mark graduated from Stanford University with an AB degree in Human Biology and then received his MD degree from the University of Pennsylvania School of Medicine. He completed residency training in internal medicine, a Chief Medical Resident year, and fellowship training in pulmonary and critical care medicine at the University of California, San Francisco. He also received an MPH degree from the University of California, Berkeley School of Public Health.
As Professor of Medicine at UCSF, Mark became an internationally recognized expert on clinical research in acute and chronic lung disease. He served as a steering committee member and ultimately UCSF Principal Investigator for the National Heart, Lung, and Blood Institute ARDS Clinical Trials Network which conducted several clinical landmark trials. Mark also built a world class NIH-funded clinical research program focusing on the epidemiology and long-term health outcomes of obstructive lung disease. He published ~200 peer reviewed articles, served on multiple NIH study sections, and was a member of the American Thoracic Society Board of Directors. He also contributed authorship to several high impact reports including two Surgeon General reports on the health effects of cigarette smoking, a California Environmental Protection Agency report on secondhand smoke exposure that led to its classification as a toxic air contaminant, and an Institute of Medicine report on the chronic health effects of Gulf War deployment.
"I'm excited to join the Genentech Foundation Board and to create opportunities for young people to overcome personal challenges and embark upon sustainable scientific careers.”
Sarah Hymowitz is currently the Vice President of Protein Sciences. In this role, she leads an organization of 180-people including the Departments of Antibody Engineering, Structural Biology, Protein Chemistry, BioMolecular Resources and Microchemistry, Proteomics and Lipidomics. Collectively, these groups create biological reagents and data that further our understanding of the structure, function, and regulation of proteins of therapeutic interest and contribute to the discovery of large and small molecule therapeutics. Sarah is a member of the Research Leadership Team and contributes to research portfolio decisions as a participant in the Small Molecule Leadership team and as a standing reviewer for the Research Review Committee. She chairs the Proteins Leadership Team, which is responsible for large molecule drug discovery in collaboration with discovery biology groups.
Sarah earned a B.A in Chemistry from Swarthmore College followed by a Ph.D. in Biophysics from the University of California, San Francisco. She joined Genentech as a postdoctoral researcher in 1999 and was subsequently hired as a Scientist in 2002. Throughout her career, Sarah has played leadership roles in basic research, antibody and small molecule drug discovery projects, and has contributed to over 75 scientific publications and patent applications. She is passionate about mentoring and developing talent.
Sean Johnston is the senior vice president, general counsel and chief compliance officer for Genentech, Inc., a member of the Roche Group. He is also a member of Genentech’s executive management committee.
Sean is responsible for oversight of Genentech’s legal and compliance organizations, consisting of over 200 attorneys, patent agents, and professional staff practicing in areas of business law, patent law, healthcare law, litigation, regulatory compliance, and privacy. Sean is deeply committed to supporting and evolving Genentech's culture and developing employees. In 2013, he received from the Genentech Women Professional Group its Professional Development Award in recognition of his commitment to the career development of women at Genentech. Sean is also chairman of the Genentech Foundation, an independent, private charitable organization.
Sean received a bachelor’s degree in biochemistry from the University of California at Davis, a doctorate degree in molecular biology from UCLA, and a law degree from Stanford University.
"Genentech has a long history of philanthropy and I’m proud to help continue that through my role on the Genentech Foundation Board. I’m especially passionate about the Foundation's commitment to postsecondary science education. I believe that by investing in long-term initiatives that provide growth-oriented career opportunities we can empower and enable people to create their own futures."
Sara Kenkare-Mitra is currently Senior Vice President of Development Sciences, a translational sciences organization that spans R&D at Genentech. In this role she has responsibility for ensuring the successful translation of promising molecule-discoveries from Research into Development through nonclinical PK/PD and safety strategies and for key components of clinical development including ensuring the right dose/exposure of drug candidates and the right proof of activity and patient selection strategies through biomarkers and diagnostics.
Sara has had a significant impact on the development of a number of biologics and small molecules leading to Genentech's key product approvals including Avastin, Tarceva, Lucentis, Xolair, Erivedge, Perjetta and Kadcyla. In addition, more than 60 Investigational New Drug applications with potential to treat a multitude of diseases in particular cancer, have been filed by her organization with US and ex-US regulatory agencies. At Genentech she is a key member of the technical and portfolio decision making committees.
Sara also holds adjunct faculty positions at UCSF in the Department of Bioengineering and Therapeutic Sciences and the University of the Pacific in Stockton. She has a passion for developing therapies to meet significant unmet medical needs with a strong scientific basis and an emphasis on personalized medicine. Sara was elected to the Institute of Medicine, National Academy in 2014. Selected as one of the 150 Most Influential Business women by San Francisco Business times in 2011, one of the 150 top alumni of UCSF in 2015, she has also won awards and recognition at Genentech not only for her excellence in leadership and mentorship, but also for her passionate commitment to the healthcare industry as a whole.
"Being a part of the Genentech Board is an incredible opportunity to give back to the communities that we are part of. My hope is that exposing underserved youth and adults to STEM careers will empower them to make a difference both in the world and in their own lives."
Allen is Vice President and Head of Site Services at Genentech. He is accountable for Genentech's corporate real estate portfolio, site engineering, facilities management, utilities operations, security, environmental health and safety, environmental sustainability, workplace strategies, transportation, and several key workplace services.
Allen has over twenty-eight years of site and global experience in the pharmaceutical industry across clinical and commercial Manufacturing and Quality. He is an execution-oriented and multi-cultural leader with a proven track record of partnership and collaboration in drug substance, drug product, and supply chain management operations. With a unique combination of creativity, empathy and results focus, Allen builds strong teams and unlocks high performance and engagement through his servant leadership style. He has successfully delivered on ambitious and innovative change initiatives. He is also recognized for leading organizational transformations with a genuine interest in employee development, diversity and well-being. Allen first joined Genentech in 1992 and has since worked in South San Francisco, Singapore, and Hillsboro locations.
Allen graduated from the University of California at Davis with a Bachelor of Science degree in Biology and earned an MBA from Saint Mary’s College of California. Outside of work, he can be found listening to vinyl records with his son at the local music store, spending time with his wife walking through downtown Millbrae, and riding his motorcycle through the Bay Area.
"It's a privilege to be a part of the Genentech Foundation as there is no greater honor than to be of service to our community and to foster a better future for others."
Eric J. Olson is currently the Vice President of US Product Development Regulatory. In this role, Eric manages the policy, intelligence and commercial regulatory affairs (CORA) groups in PDR. He sits on the PDR Leadership Team contributing to the overall direction of the global Regulatory group within the company.
While previously based in Basel, Switzerland he served as business lead for Product Development’s (PD) Smarter Information Management initiative, a multi-year innovation project aimed toward transforming the way PD uses its vast clinical information. Additionally, Eric was the Head of CORA, Director of PD Projects for Genentech’s former President Sue Hellmann and one of the company’s lobbyists in Washington, DC. Eric also serves as the Site Head for Product Development in South San Francisco and on the Board of the Genentech Foundation, a private charitable foundation the company created to give back to its local community.
Prior to joining Genentech, Eric was Chief of Staff to U.S. Representative Anna G. Eshoo - managing all legislative, constituent and administrative functions in her Washington, D.C. office. He has held legislative roles for former U.S. Senate Democratic Leader Thomas Daschle, Rep. Eshoo, and former Rep. Norm Mineta.
Eric graduated from Santa Clara University in 1995 with a B.A. in Political Science and minor in Communication. He lives in Redwood City, CA with his wife and two daughters. Hobbies include playing and coaching sports, reading and learning about wine. He played football at Santa Clara University but after many years and many knee surgeries, he currently prefers non-contact sports such as distance running and triathlon.
"I'm honored to serve on the Genentech Foundation Board and build upon the company's legacy of providing support to the next generation of pioneering scientists from our local community."
Geoffrey P. Teeter is Vice President, Corporate Relations at Genentech. In this role, Geoff leads the company’s communication strategy and oversees the activities of the Corporate Relations department including corporate and product public relations, corporate branding, science communications, internal communications, corporate and employee giving and digital strategy and channels.
Geoff is a member of the global Communication Leadership Team and serves as the North American Communications Lead for the Roche Group in the United States. He is a member of the Board of Directors of both the Genentech Foundation and the Genentech Access to Care Foundation.
During his 24 years with the company, Geoff has developed and implemented a number of communications initiatives and strategies that have helped strengthen Genentech's corporate reputation and supported the company's goal of being a great place to work.
Prior to joining Genentech, Geoff worked on behalf of several pharma and healthcare companies at Burson-Marsteller public relations agency in Manhattan, and as a product communications manager at CIBA-Geigy Pharmaceuticals Division. He holds a bachelor's degree in mass communication from St. Bonaventure University.